News Daily News Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis Caitlin E. Cox May 03, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for April 2022 Shelley Wood May 02, 2022
News Conference News HRS 2022 Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era Todd Neale May 02, 2022
News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Daily News Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries Todd Neale April 20, 2022
News Daily News Revascularization’s Benefits in HFrEF Linked to Gains in LV Function Caitlin E. Cox April 15, 2022
News Daily News Myocarditis in Unvaxxed Patients Hospitalized With COVID-19: New Insights L.A. McKeown April 13, 2022
News Conference News ACC 2022 Global STEMI Outcomes May Improve With Tracking, GHATI Hints Shelley Wood April 11, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
Presentation ACC 2022 The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF Presenter: Michael Felker April 04, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM Yael L. Maxwell April 02, 2022
News Conference News ACC 2022 SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization L.A. McKeown April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022